ArticleDiscover oncology2026
Development of a risk model for outcome prediction and treatment guidance in lung adenocarcinoma based on hypoxia, glycolysis, and lymph node metastasis-related genes.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypoxia and glycolysis are closely linked to tumor progression. This study aims to explore the prognostic value of hypoxia-, glycolysis-, and lymph node metastasis (LNM)-related genes in lung adenocarcinoma (LUAD) patients.
methodsThe data of LUAD patients were collected from TCGA and GEO databases. ssGSEA analysis was conducted to evaluate the hypoxia and glycolysis status. The signature genes were identified using differential expression analysis, univariate COX regression analysis, and least absolute shrinkage and selector operator (LASSO) regression analysis, followed by the construction of a risk score model. The prognosis value of the risk score model was evaluated. Finally, the correlations between the risk score model and clinical characteristics, immune infiltration status, tumor stemness, and sensitivity of immunotherapy and chemotherapy were investigated.
resultsThe hypoxia- and glycolysis-related gene sets were significantly up-regulated in LUAD patients with LNM. Four signature genes were identified, and a risk score model was constructed, exhibiting good prognostic value. LUAD patients in the high-risk group had a poorer prognosis than those in the low-risk group. The clinical correlation analysis showed that age, N stage, T stage, stage, and primary therapy outcome success were related to risk score. Immune infiltration analysis found that macrophages M0 and mast cells resting were significantly correlated with risk score. LUAD patients in the high-risk group exhibited higher tumor stemness and IC50 value.
conclusionThe hypoxia-, glycolysis-, and LNM-related signature genes were identified and a risk score model was constructed, providing potential prognostic targets for LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.